Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABBV | NYSE | USD | Real-time | |
0QCV | London | EUR | Real-time | |
ABBV | BIVA | MXN | Delayed | |
ABBV | Mexico | MXN | Delayed | |
1ABBV | Milan | EUR | Real-time | |
4AB | TradeGate | EUR | Delayed | |
4AB | Frankfurt | EUR | Delayed | |
ABBV34 | B3 | BRL | Delayed | |
ABBV | Vienna | EUR | Real-time | |
ABBV | Lima | USD | Delayed |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bullish | 15 | Current | |||
Bullish Engulfing | 15 | Current | |||
Engulfing Bearish | 5H | Current | |||
Completed Patterns | |||||
Engulfing Bearish | 1D | 2 | Apr 24, 2024 | ||
Bullish Engulfing | 5H | 2 | Apr 26, 2024 05:00 | ||
Bullish Engulfing | 1W | 4 | Mar 24, 2024 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NYSE | 160.12 | 0.00 | 0.00 | 4,260,666 | -4.29% | USD | 17:10:18 | ||
London | 163.47 | 155.30 | 171.64 | 2,075 | -1.98% | EUR | |||
BIVA | 2,880.00 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Mexico | 2,790.00 | 2,720.07 | 2,851.99 | 7 | -3.13% | MXN | |||
Milan | 156.44 | 0.00 | 0.00 | 263 | +1.20% | EUR | |||
TradeGate | 151.00 | 150.02 | 150.20 | 4,288 | -2.73% | EUR | |||
Frankfurt | 152.82 | 149.90 | 150.36 | 53 | -3.06% | EUR | |||
B3 | 51.45 | 51.45 | 51.75 | 119 | -4.19% | BRL | |||
Vienna | 164.70 | 161.00 | 164.70 | 0 | +0.00% | EUR | |||
Lima | 168.80 | 0.00 | 0.00 | 0 | 0.00% | USD |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Barclays | 204.35 | 205.00 | 199.08 | +0.35 | +0.17% | 57.35M | 16:35:59 | ||
AstraZeneca | 11,988.0 | 12,144.0 | 11,882.0 | -38.0 | -0.32% | 1.95M | 16:35:59 | ||
Legal & General | 234.40 | 236.69 | 234.10 | +1.60 | +0.69% | 17.04M | 16:35:59 | ||
Rolls-Royce Holdings | 421.10 | 421.10 | 409.20 | +15.40 | +3.80% | 30.17M | 16:35:59 | ||
Anglo American | 2,643.0 | 2,721.0 | 2,518.5 | +83.0 | +3.24% | 11.48M | 16:35:59 | ||
Lloyds Banking | 52.30 | 52.60 | 51.08 | +1.10 | +2.15% | 148.56M | 16:35:59 | ||
IAG | 176.30 | 179.00 | 176.30 | +0.15 | +0.09% | 10.91M | 16:35:59 | ||
NatWest Group | 307.40 | 308.70 | 295.50 | +17.60 | +6.07% | 45.97M | 16:35:59 | ||
HSBC | 663.60 | 665.80 | 661.10 | +1.70 | +0.26% | 13.03M | 16:35:59 | ||
BAE Systems | 1,340.00 | 1,345.50 | 1,307.00 | +20.00 | +1.52% | 6.11M | 16:35:59 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review